SCHEMBL3565500

SCHEMBL3565500

COc1cc(-c2ccnc3[nH]cc(C#N)c23)c(Cl)cc1Cl

nearest known ligand 0.61

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
LRRK2 Q5S007 14/20 0.61
HSP90AB1 P08238 3/20 0.61
HSP90AA1 P07900 2/20 0.61
KCNH2 Q12809 1/20 0.49
ROCK2 O75116 2/20 0.48
ROCK1 Q13464 2/20 0.48
CDC42BPA Q5VT25 2/20 0.48
CDC42BPB Q9Y5S2 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3575655 0.82 HSP90AB1 (0.69) HSP90AB1HSP90AA1KCNH2
SCHEMBL28049841 0.81 LRRK2 (0.70) LRRK2ROCK2ROCK1CDC42BPACDC42BPB
SCHEMBL3565489 0.79 LRRK2 (0.72) LRRK2ROCK2ROCK1CDC42BPACDC42BPB
SCHEMBL14421844 0.75 HSP90AB1 (0.62) LRRK2HSP90AB1HSP90AA1KCNH2
SCHEMBL3578783 0.75 HSP90AB1 (0.51) HSP90AB1HSP90AA1KCNH2
SCHEMBL3581459 0.74 LRRK2 (0.61) LRRK2ROCK2ROCK1CDC42BPACDC42BPB
SCHEMBL30543157 0.74 LRRK2 (1.00) LRRK2ROCK2ROCK1CDC42BPACDC42BPB
SCHEMBL2105745 0.74 LRRK2 (1.00) LRRK2ROCK2ROCK1CDC42BPACDC42BPB
SCHEMBL2568418 0.73 HSP90AB1 (0.75) HSP90AB1HSP90AA1KCNH2
SCHEMBL16178033 0.73 LRRK2 (1.00) LRRK2ROCK2ROCK1CDC42BPACDC42BPB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100010037-A1 1H-PYRROLO[2,3-B]PYRIDINE DERIVATIVES USEFUL AS HSP90 INHIBITORS VERNALIS (R&D) LTD. (GB) 2010-01-14 US claimed
US-20100010037-A1 1H-PYRROLO[2,3-B]PYRIDINE DERIVATIVES USEFUL AS HSP90 INHIBITORS VERNALIS (R&D) LTD. (GB) 2010-01-14 US disclosed
US-20100010037-A1 1H-PYRROLO[2,3-B]PYRIDINE DERIVATIVES USEFUL AS HSP90 INHIBITORS VERNALIS (R&D) LTD. (GB) 2010-01-14 US disclosed
US-20100010037-A1 1H-PYRROLO[2,3-B]PYRIDINE DERIVATIVES USEFUL AS HSP90 INHIBITORS VERNALIS (R&D) LTD. (GB) 2010-01-14 US disclosed
EP-2057155-A1 1H-PYRROLO[2,3-B]PYRIDINE DERIVATIVES USEFUL AS HSP90 INHIBITORS Vernalis (R&D) Limited (GB) 2009-05-13 EP disclosed
WO-2008025947-A1 1H-PYRROLO[2,3-B]PYRIDINE DERIVATIVES USEFUL AS HSP90 INHIBITORS VERNALIS (R & D) LTD. (GB) 2008-03-06 WO disclosed
WO-2008025947-A1 1H-PYRROLO[2,3-B]PYRIDINE DERIVATIVES USEFUL AS HSP90 INHIBITORS VERNALIS (R & D) LTD. (GB) 2008-03-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100010037-A1 1H-PYRROLO[2,3-B]PYRIDINE DERIVATIVES USEFUL AS HSP90 INHIBITORS HSP90AB1, HSP90AA1, HSP90AB2P LRRK2 2502/4885HSP90AB1 1/4885HSP90AA1 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.